News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for April 2022 Shelley Wood May 02, 2022
News Conference News ACC 2022 PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI Todd Neale April 03, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels Michael O'Riordan December 22, 2021
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021
News Daily News LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD Michael O'Riordan June 18, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021
News Daily News Inclisiran Approved in Europe for Lowering LDL Cholesterol Michael O'Riordan December 11, 2020
News Daily News High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention Michael O'Riordan August 11, 2020
News Daily News FOURIER Surveys Reassure About Cognitive Safety of Evolocumab Todd Neale May 06, 2020
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Conference News ACC 2020 Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH Yael L. Maxwell April 06, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
Presentation ACC 2020 Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH) Presenter: Dirk J. Blom March 30, 2020